Product wins Top Award at US Trade show
Belluscura PLC
("Belluscura" or the "Company")
Product wins Top Award at US Trade show
X-PLO₂R™ wins gold award at Medtrade East 2021 in Atlanta
LONDON, U.K. AND PLANO, TX, U.S. (25 October 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology , announces that its X-PLO₂R™ portable oxygen concentrator won the Providers' Choice Gold, the highest accolade to be given at Medtrade East in Atlanta, the largest home medical equipment trade show and conference in the U.S.
The X-PLO₂R™ weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world's first modular portable oxygen concentrator and that it generates more oxygen by weight than any other US Food & Drug Administration ("FDA") cleared POC in its class.
The X-PLO2R ™ can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. The X-PLO₂R™ is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices.
Robert Rauker, CEO of Belluscura plc, said : "It is fantastic news and a great achievement that our portable oxygen concentrator has received the highest accolade given by the largest home medical equipment trade show and conference in the U.S. This award solidifies the strong demand we are receiving for the product and we will update shareholders with expected unit deliveries for 2021 and 2022 in the near future."
For further information please contact:
|
Belluscura plc |
|
|
Robert Rauker, Chief Executive Officer |
via Walbrook PR |
|
Anthony Dyer, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Nicholas Chambers |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
|
Paul McManus / Sam Allen |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Legal & General Group
- 1 day ago Legal & General Group
- 1 day ago GETECH Group
- 1 day ago Great Portland Estates
- 1 day ago Time Out Group